Dual-phase 18F-FDG PET can predict lung adenocarcinoma outcome

03/31/2010 | HealthImaging.com

A study involving patients with histologically confirmed lung adenocarcinoma found that the change in maximal standardized uptake values between early and delayed 18F-FDG PET can be a strong singular predictor of patient outcome and aid in patient management. "Patients with more than 25 percent increase in SUVmax had a median survival of 15 months, compared with 39 months for those with less than 25 percent increase in SUVmax," the researchers said.

View Full Article in:

HealthImaging.com

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Counsel – Regulatory Affairs
RAI Services Company
Winston Salem, NC
Director of Program Development
AdvaMed
Washington DC, DC
Director of System QA
LifeWatch Services, Inc.
Rosemont, IL
Director of Business Development and Membership
AdvaMed
Washington DC, DC
Director, Corporate Counsel
Regeneron
Tarrytown, NY